| Clevidipine (the Medicines Company). | |
| | |
MedLine Citation:
|
PMID: 12431021 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The Medicines Company (under license from AstraZeneca) is developing clevidipine, a short-acting dihydropyridine calcium antagonist, for the potential treatment of peri-operative hypertension. By 1997, the compound was undergoing phase II clinical evaluation by the original developer, AstraZeneca. By March 2002, The Medicines Company was conducting phase III clinical trials. |
| | |
Authors:
|
Hongwei Zhang |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in investigational drugs (London, England : 2000) Volume: 3 ISSN: 1472-4472 ISO Abbreviation: Curr Opin Investig Drugs Publication Date: 2002 Oct |
Date Detail:
|
Created Date: 2002-11-14 Completed Date: 2003-04-11 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100965718 Medline TA: Curr Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 1474-8 Citation Subset: IM |
Affiliation:
|
Department of General Surgery, The Second Affiliated Hospital of Zhong Shan University, Guangzhou, PR China. hongweizhang67@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antihypertensive Agents / pharmacology* Calcium Channel Blockers / pharmacology* Clinical Trials as Topic Humans Pyridines / metabolism, pharmacology*, therapeutic use Structure-Activity Relationship |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Pyridines; 0/clevidipine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The role of aldosterone receptor blockade in the management of cardiovascular disease.
Next Document: Aliskiren (Speedel).